Kymera Therapeutics (NASDAQ:KYMR) Stock Price Target Raised at Royal Bank Of Canada

Key Points

• Royal Bank of Canada raised Kymera Therapeutics’ price target from $112 to $116 while maintaining a “sector perform” rating; the new target implies roughly 4.1% downside from the stock’s $120.99 price.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and average price target of $137.36. Mizuho, Oppenheimer, BTIG Research and Truist have set targets between $139 and $150.
• Kymera’s latest quarter disappointed financially, with a $1.32 per-share loss versus the $1.26 estimate and revenue of $1.35 million versus expectations of $3.28 million, though positive Phase 1 results for its KT-579 drug candidate provided a development catalyst.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) had its price target upped by research analysts at Royal Bank Of Canada from $112.00 to $116.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a "sector perform" rating on the stock. Royal Bank Of Canada's price target indicates a potential downside of 4.13% from the company's current price.

A number of other research analysts have also weighed in on KYMR. Weiss Ratings restated a "sell (d-)" rating on shares of Kymera Therapeutics in a research report on Thursday, October 15th. TD Cowen raised Kymera Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. Mizuho boosted their target price on Kymera Therapeutics from $120.00 to $140.00 and gave the company an "outperform" rating in a research report on Thursday, July 16th. Oppenheimer reaffirmed an "outperform" rating and set a $140.00 price objective on shares of Kymera Therapeutics in a research note on Thursday. Finally, BTIG Research increased their price objective on shares of Kymera Therapeutics from $134.00 to $139.00 and gave the stock a "buy" rating in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $137.36.

Kymera Therapeutics Trading Down 1.3%

Shares of NASDAQ:KYMR traded down $1.61 during trading on Friday, reaching $120.99. 339,381 shares of the company traded hands, compared to its average volume of 746,757. The business's fifty day moving average is $114.83 and its 200-day moving average is $96.08. Kymera Therapeutics has a 52-week low of $55.66 and a 52-week high of $130.05. The firm has a market capitalization of $10.06 billion, a price-to-earnings ratio of -37.20 and a beta of 1.98.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported ($1.32) earnings per share for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.06). Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%. The firm had revenue of $1.35 million for the quarter, compared to analysts' expectations of $3.28 million. During the same quarter last year, the company posted ($0.94) EPS. The firm's revenue was up .0% on a year-over-year basis. On average, sell-side analysts predict that Kymera Therapeutics will post -3.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Brian Adams sold 6,371 shares of the company's stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $116.83, for a total value of $744,323.93. Following the transaction, the insider directly owned 50,254 shares in the company, valued at approximately $5,871,174.82. This represents a 11.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the completion of the transaction, the chief executive officer owned 666,568 shares of the company's stock, valued at $75,855,438.40. This trade represents a 4.31% decrease in their position. The disclosure for this sale is available in the SEC filing. 15.98% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of KYMR. Merck & Co. Inc. purchased a new position in Kymera Therapeutics during the 2nd quarter valued at about $88,544,161. Legal & General Group Plc bought a new stake in shares of Kymera Therapeutics in the 2nd quarter valued at approximately $4,155,000. Deutsche Bank AG acquired a new position in Kymera Therapeutics during the 2nd quarter valued at about $12,161,000. Eagle Health Investments LP bought a new position in shares of Kymera Therapeutics in the second quarter valued at approximately $19,052,000. Finally, Bank of America Corp DE acquired a new position in Kymera Therapeutics in the second quarter worth approximately $43,378,000.

Kymera Therapeutics News Summary

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera reported positive Phase 1 results for KT-579, an oral IRF5 degrader. The drug produced deep, sustained IRF5 degradation, robust changes in disease-relevant biomarkers and a favorable safety profile in healthy volunteers, strengthening the case for continued development in immunological diseases. Kymera Announces Q3 2026 Results and KT-579 Phase 1 Data
• Positive Sentiment: Truist Securities raised its price target on KYMR to $150 from $136 while maintaining a Buy rating, signaling increased confidence in Kymera’s pipeline and potential upside. Truist Raises Kymera Price Target
• Positive Sentiment: BTIG Research also increased its target to $139 from $134 and initiated or maintained a Buy rating, adding further analyst support for the shares.
• Neutral Sentiment: The company’s Q3 earnings call focused on the financial results and KT-579 development update. Investors are likely to look for additional guidance on clinical timelines, future trials and cash resources as Kymera advances its pipeline. Kymera Q3 2026 Earnings Call Transcript
• Negative Sentiment: Kymera reported a third-quarter loss of $1.32 per share, wider than the $1.26 analyst consensus, while revenue of $1.35 million fell short of the $3.28 million estimate. The company’s negative profitability metrics and widening net loss remain risks for investors in this clinical-stage biotech. Kymera Q3 2026 Financial Results

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell's natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company's research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.